Photobiostimulation Market Size
| Study Period | 2021 - 2029 |
| Market Size (2024) | USD 240.80 Million |
| Market Size (2029) | USD 393.40 Million |
| CAGR (2024 - 2029) | 10.31 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Photobiostimulation Market Analysis
The Photobiostimulation Market size is estimated at USD 240.80 million in 2024, and is expected to reach USD 393.40 million by 2029, growing at a CAGR of 10.31% during the forecast period (2024-2029).
The significant factor attributing to the market growth is the growing incidence of chronic diseases, leading to an increase in the number of patients being treated using methods of photobiostimulation. Additional factors, such as the rising prevalence of chronic pain disorders such as arthritis, osteoporosis, and the increasing geriatric population, will drive the market for photobiostimulation during the forecast period. For instance, according to a report published by the Osteoarthritis Action Alliance in January 2024, it is estimated that 1 in 5 United States adults have some form of arthritis, and osteoarthritis (OA) is the most common form of arthritis, affecting 32.5 million United States adults. Hence, the high prevalence of osteoarthritis in the United States is expected to drive the demand for photobiostimulation therapy in the forecasted period in the region.
Photobiostimulation therapy has also been utilized in diabetic wound healing treatment. A photobiomodulation response is produced when cells are exposed to radiation, which changes cellular functions and promotes the healing of diabetic wounds. By modifying many cellular and molecular processes, photobiomodulation therapy (PBMT) employing red and near-infrared (NIR) wavelengths is considered a promising treatment for accelerating the rate of diabetic wound healing, eliminating pain, and reducing inflammation. According to a report published by the International Diabetic Federation (IDF) in 2022, 537 million people have diabetes worldwide in 2021, and more than 51 million people will be in the North American region; by 2045, it will rise to 63 million. The diabetic population is high in the United States, which ultimately results in a higher number of diabetic foot ulcers. This is likely to increase the demand for photobiostimulation therapy as a cure, and it is expected to grow in the market over the forecast period.
Advancements in technology and new product launches by the market players focusing on photobiostimulation therapy are also aiding the growth of the studied market over the forecast period. For instance, in June 2023, Lumaflex, a health tech company, launched its new Lumaflex Body Pro. This revolutionary red light therapy device is currently in production and has achieved FDA Class 2 Certification. It has become a popular treatment for muscle recovery among fitness communities such as bodybuilders and mixed martial arts (MMA) athletes.
Moreover, in February 2024, BIOPTRON AG presented positive clinical data on using photobiostimulation treatment devices for wound healing at the Dubai World Dermatology Congress. The study discovered that the therapy dramatically decreased healing time while improving patient outcomes. Therefore, rising clinical trials and company activities are likely to add to the market growth.
Thus, the growing incidence of chronic diseases like diabetes and technological advancements accompanied by new products launched are expected to propel the growth of the photobiostimulation market. However, the rising availability of alternative treatments will hinder the market's growth over the forecast period.
Photobiostimulation Market Trends
Pain Management is Expected to Hold the Major Market Share in the Market Over the Forecast Period
Photobiostimulation has been explored for pain management with promising results. The benefits include the reduction of pain intensity, inflammation, and the promotion of tissue repair. In this application, low-level light therapy helps modulate cellular processes, influencing the release of endorphins and reducing inflammatory mediators. Conditions like musculoskeletal pain, arthritis, and neuropathic pain may benefit from photobiostimulation.
Low-level light therapy (LLLT) has been shown to have anti-inflammatory effects, helping to decrease swelling, alleviate pain associated with inflammatory conditions, and trigger the release of endorphins, the body's natural painkillers, providing a natural way to manage pain without relying solely on medication.
The growing burden of several diseases that elevate pain, such as arthritis and surgeries, and the growing application of LLLT in pain management is expected to contribute to the segment growth over the forecast period. Physical pain has trended upward globally over the last decade. For instance, according to the study published in Economic and Human Biology in January 2024, the pain prevalence across 146 countries worldwide revealed that 33.3% of people were in pain in 2019, 32.8% in 2020, 32.5% in 2021, and 34.1% in 2022. Thus, growing pain prevalence across the world is expected to increase demand for photobiostimulation therapy, thereby boosting the segment growth.
Moreover, according to the United States Pain Foundation report published in July 2022, 50 million Americans live with chronic pain or pain that lasts most days or every day for three months or more. Thus, the high burden of chronic wounds and the application of photobiostimulation therapy in wound care is anticipated to boost segment growth over the first period.
The growing burden of diseases that lead to pain is expected to contribute to segment growth. For instance, according to the Australian Bureau of Statistics published in December 2022, approximately 3.7 million (14.5%) people had arthritis in 2022. The proportion is almost seven times higher for people aged 45–54 years than for those aged 0–44 years (16.2% compared to 2.5%). Severe/very severe bodily pain was experienced by the patient suffering from arthritis. Thus, the growing burden of pain-related diseases also propels the growth of the segment.
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
The North American region possesses a highly sophisticated healthcare infrastructure with an extensive network of advanced hospitals and surgical facilities well-equipped with cutting-edge technology, facilitating the widespread adoption of photobiostimulation treatment. The region is expected to have significant market growth over the forecast period, mainly attributed to the rising prevalence of chronic diseases like osteoporosis and arthritis, and the increase in technological advancements is expected to boost market growth over the forecast period. In addition, market growth is also fueled by the increasing geriatric population, rising focus on non-invasive treatments, growing demand for pain management treatments, and increasing focus on sports medicine. The increasing prevalence of sports-related injuries and the rise in the number of wound injuries in the region eventually increase the demand for various photobiostimulation treatments, for instance, according to the injury facts provided by the National Safety Council of the United States, sports and recreational injuries increased by 12% in 2022. The injuries related to exercise and exercise equipment increased slightly from 2021, from 409,224 injuries in 2021 to 445,642 injuries in 2022. This rising incidence of sports-related injuries is driving the demand for photobiostimulation as an effective and non-invasive therapeutic modality for accelerated recovery and pain management in athletes.
Moreover, rising demand for minimally invasive surgery (MIS) among patients also propels the market’s growth. The rise in the preference for MIS surgeries is rooted in the perceived advantages of MIS, such as faster recovery times, reduced pain, and smaller incisions, all of which contribute to the increasing acceptance and demand for photobiostimulation. For instance, according to a report published by the American Society of Plastic Surgeons in September 2023, 26.2 million surgical and minimally invasive cosmetic and reconstructive procedures were performed in the United States in 2022.
The aging demographic in the region further amplifies the need for surgical interventions, thereby fueling the demand for less invasive options like photobiostimulation treatment. For instance, according to a report published by America’s Health Rankings in December 2023, nearly 58 million adults ages 65 and older were living in the United States in 2022, accounting for about 17.3% of the nation's population. By 2040, that proportion is projected to grow to 22%. This trend aligns with continuous technological advancements in photobiostimulation treatment. In conclusion, the photobiostimulation market in North America is driven by the increasing prevalence of sports-related injuries, rising demand for minimally invasive surgery, the aging demographic, and significant investments in research and development activities.
Photobiostimulation Industry Overview
The photobiostimulation market is consolidated and consists of a few major players. A few of the major players are currently dominating the market in terms of market share. Some prominent players vigorously make acquisitions and new product launches with other companies to consolidate their global market positions. BioLight Technologies LLC, THOR Photomedicine Ltd, BIOFLEX, Vielight Inc., and Erchonia Corporation are currently dominating the market.
Photobiostimulation Market Leaders
-
BioLight Technologies LLC
-
Erchonia Corporation
-
Vielight Inc
-
BIOFLEX
-
THOR Photomedicine Ltd
*Disclaimer: Major Players sorted in no particular order
Photobiostimulation Market News
• In January 2024, Iridex Corporation launched two new next-generation platform lasers, Iridex 532 nm and Iridex 577 nm. The products use Iridex’s patented technology for laser delivery modality designed to control photothermal effects in laser photocoagulation by allowing the tissue to cool between laser pulses, minimizing or preventing potential tissue damage.
• In January 2024, PhotoMedex established a strategic agreement with Zimmer Biomet to develop and commercialize photobiostimulation devices for orthopedic purposes.
Photobiostimulation Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Incidence of Osteoporosis and Arthritis
- 4.2.2 Rising Demand for Non-Invasive Treatments
-
4.3 Market Restraints
- 4.3.1 Availability of Alternative Treatments
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Buyers/Consumers
- 4.4.2 Bargaining Power of Suppliers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Application
- 5.1.1 Wound Care
- 5.1.2 Pain Management
- 5.1.3 Cosmetic Application
- 5.1.4 Other Applications
-
5.2 By Wavelength Type
- 5.2.1 Infrared Light
- 5.2.2 Red Light
- 5.2.3 Other Wavelength Types
-
5.3 By End-User
- 5.3.1 Specialty Clinics
- 5.3.2 Research Institutes
- 5.3.3 Other End-Users
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 BioLight Technologies LLC
- 6.1.2 THOR Photomedicine Ltd
- 6.1.3 BIOFLEX
- 6.1.4 Erchonia Corporation
- 6.1.5 Ingeneus
- 6.1.6 Vielight Inc.
- 6.1.7 HairMax
- 6.1.8 TheraDome Inc.
- 6.1.9 LumiWave
- 6.1.10 Omega Laser Systems
- 6.1.11 iGrow Laser
- 6.1.12 Pulse Laser Relief
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityPhotobiostimulation Industry Segmentation
As per the scope of this report, photobiostimulants are being used to minimize tissue damage and reduce swelling, pain, and edema to treat deeper skin wounds and nerves. The photobiostimulation market is segmented by Technique, Wavelength Type, End-User, and Geography. The technique segment is further segmented into Wound Care, Pain Management, Cosmetic Application, and Other Techniques. The wavelength is further separated into Infrared Light, Red Light, and Other Wavelength Types. The End User Segment is further divided into Specialty Clinics, Research Institutes, and Other End Users. The geography region is segregated into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers the value in USD for the above segments.
| By Application | Wound Care | |
| Pain Management | ||
| Cosmetic Application | ||
| Other Applications | ||
| By Wavelength Type | Infrared Light | |
| Red Light | ||
| Other Wavelength Types | ||
| By End-User | Specialty Clinics | |
| Research Institutes | ||
| Other End-Users | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Photobiostimulation Market Research FAQs
How big is the Photobiostimulation Market?
The Photobiostimulation Market size is expected to reach USD 240.80 million in 2024 and grow at a CAGR of 10.31% to reach USD 393.40 million by 2029.
What is the current Photobiostimulation Market size?
In 2024, the Photobiostimulation Market size is expected to reach USD 240.80 million.
Who are the key players in Photobiostimulation Market?
BioLight Technologies LLC, Erchonia Corporation, Vielight Inc, BIOFLEX and THOR Photomedicine Ltd are the major companies operating in the Photobiostimulation Market.
Which is the fastest growing region in Photobiostimulation Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Photobiostimulation Market?
In 2024, the North America accounts for the largest market share in Photobiostimulation Market.
What years does this Photobiostimulation Market cover, and what was the market size in 2023?
In 2023, the Photobiostimulation Market size was estimated at USD 215.97 million. The report covers the Photobiostimulation Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Photobiostimulation Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Photobiostimulation Industry Report
Statistics for the 2024 Photobiostimulation market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Photobiostimulation analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
